Research view
Switch to patient viewAcute myeloid leukaemia: trials that stopped early
Trials on Acute myeloid leukaemia that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
167 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.
Terminated
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
Reason given in the registry “FDA Clinical Hold”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Nov 2026.
- Ended
- Oct 2026
- Phase
- Phase 1
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT02530034
Withdrawn
Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
Reason given in the registry “Budgetary constraints”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Oct 2026.
- Phase
- Phase 1
- Run by
- Virginia Commonwealth University
- Registry record
- NCT07130695
Terminated
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Reason given in the registry “No longer have funding support to complete the pharmacogenetics component.”
Quoted unchanged from ClinicalTrials.gov; record updated 21 Oct 2026.
- Ended
- Mar 2025
- Phase
- Phase 2
- Run by
- Medical College of Wisconsin
- Registry record
- NCT03150004
Suspended
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
Reason given in the registry “Accrual goal Met”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Oct 2026.
- Phase
- Phase 1
- Run by
- City of Hope Medical Center
- Registry record
- NCT03969446
Suspended
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
Reason given in the registry “resources”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Oct 2026.
- Phase
- Phase 1
- Run by
- City of Hope Medical Center
- Registry record
- NCT06454409
Suspended
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
Reason given in the registry “Safety Issues, status is being updated per PI due to safety issues. Study is now Temporarily Closed to Accrual.”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Oct 2026.
- Phase
- Phase 1
- Run by
- City of Hope Medical Center
- Registry record
- NCT05263284
Suspended
Pyronaridine in Acute Myeloid Leukemia (AML)
Reason given in the registry “Change of protocol”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Oct 2026.
- Phase
- Phase 2
- Run by
- Armaceutica, Inc.
- Registry record
- NCT05291390
Terminated
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
Reason given in the registry “Early discontinuation based on strategic sponsor decision not driven by any safety concerns”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Oct 2026.
- Ended
- Aug 2025
- Phase
- Phase 1/2
- Run by
- Sanofi
- Registry record
- NCT06508489
Terminated
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
Reason given in the registry “\<75% participation”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2026.
- Ended
- Oct 2026
- Phase
- Phase 2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT04062266
Suspended
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
Reason given in the registry “Timeline Adjustment”
Quoted unchanged from ClinicalTrials.gov; record updated 15 Oct 2026.
- Phase
- Phase 1
- Run by
- City of Hope Medical Center
- Registry record
- NCT06195891
Terminated
Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia
Reason given in the registry “Inclusion is proceeding too slowly”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Oct 2026.
- Ended
- Jul 2024
- Run by
- Centre Hospitalier Universitaire de Saint Etienne
- Registry record
- NCT03439371
Terminated
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Reason given in the registry “Inability to meet protocol objectives”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Oct 2026.
- Ended
- Aug 2026
- Phase
- Phase 1
- Run by
- Bristol-Myers Squibb
- Registry record
- NCT06419634
Suspended
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
Reason given in the registry “Planned interim analyse”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Oct 2026.
- Phase
- Phase 2
- Run by
- Institut Paoli-Calmettes
- Registry record
- NCT06055621
Suspended
Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant
Reason given in the registry “Trial being transferred to new lead site”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Sept 2026.
- Phase
- Phase 1
- Run by
- Huda Salman
- Registry record
- NCT06197672
Terminated
Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
Reason given in the registry “poor accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Sept 2026.
- Ended
- Jan 2025
- Phase
- Early phase 1
- Run by
- Base Therapeutics (Shanghai) Co., Ltd.
- Registry record
- NCT06541405
Terminated
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
Reason given in the registry “poor accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Sept 2026.
- Ended
- Jun 2025
- Phase
- Early phase 1
- Run by
- Base Therapeutics (Shanghai) Co., Ltd.
- Registry record
- NCT06541444
Terminated
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Reason given in the registry “Strategic Considerations”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Sept 2026.
- Ended
- Aug 2026
- Run by
- AbbVie
- Registry record
- NCT05424562
Terminated
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
Reason given in the registry “Sponsor decision (No safety concern)”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Sept 2026.
- Ended
- Nov 2025
- Phase
- Phase 1/2
- Run by
- Takeda
- Registry record
- NCT05886491
Terminated
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Reason given in the registry “Sponsor prioritization of other development portfolio”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Sept 2026.
- Ended
- Sept 2026
- Phase
- Phase 1
- Run by
- SystImmune Inc.
- Registry record
- NCT06714591
Terminated
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Reason given in the registry “RPD2 has been identified”
Quoted unchanged from ClinicalTrials.gov; record updated 18 Sept 2026.
- Ended
- May 2024
- Phase
- Phase 1
- Run by
- Ryvu Therapeutics SA
- Registry record
- NCT04021368
Terminated
Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
Reason given in the registry “Sponsor decision”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Sept 2026.
- Ended
- Sept 2025
- Phase
- Phase 2
- Run by
- Ryvu Therapeutics SA
- Registry record
- NCT06268574
Terminated
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
Reason given in the registry “Company Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Sept 2026.
- Ended
- Sept 2026
- Phase
- Phase 1/2
- Run by
- BlueSphere Bio, Inc
- Registry record
- NCT06704152
Withdrawn
Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
Reason given in the registry “Company Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Sept 2026.
- Ended
- Sept 2026
- Phase
- Phase 1
- Run by
- BlueSphere Bio, Inc
- Registry record
- NCT07566585
Suspended
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Reason given in the registry “insufficient funding”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Sept 2026.
- Phase
- Phase 2
- Run by
- Leland Metheny
- Registry record
- NCT06680661
Withdrawn
Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML
Reason given in the registry “Strategic adjustment.”
Quoted unchanged from ClinicalTrials.gov; record updated 26 Aug 2026.
- Ended
- Mar 2026
- Phase
- Early phase 1
- Run by
- First Affiliated Hospital of Guangxi Medical University
- Registry record
- NCT07338357
Suspended
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
Reason given in the registry “Other - Pending amendment for study expansion.”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Aug 2026.
- Phase
- Phase 1
- Run by
- National Cancer Institute (NCI)
- Registry record
- NCT06514261
Suspended
Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia
Reason given in the registry “Drug Supply Issues”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Aug 2026.
- Phase
- Phase 1
- Run by
- National Cancer Institute (NCI)
- Registry record
- NCT06802523
Terminated
A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia
Reason given in the registry “Interim Analysis per Protocol”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Aug 2026.
- Ended
- Aug 2025
- Phase
- Phase 2
- Run by
- University of Michigan Rogel Cancer Center
- Registry record
- NCT05780879
Terminated
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Reason given in the registry “\<75% participants”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Aug 2026.
- Ended
- Aug 2026
- Phase
- Phase 1/2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT02392572
Suspended
DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial
Reason given in the registry “Recruitment on hold with plans to open to accrual again soon.”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Aug 2026.
- Phase
- Phase 1
- Run by
- Fred Hutchinson Cancer Center
- Registry record
- NCT06492707
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.